Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings Nimbus $43mm

Executive Summary

Pfizer Venture Investments and Lightstone Venture led an oversubscribed $43mm Series B round for Nimbus Therapeutics (formerly Nimbus Discovery; combines computer-aided drug design, chemistry, and pharmacology to discover small molecules for various diseases). Returning backers Atlas Venture, SR One, Lilly Ventures, and Bill Gates participated. Nimbus will use the money to enter its lead acetyl CoA carboxylase (ACC) inhibitor into human testing for nonalcoholic steatohepatitis (NASH). Phase I data is expected later this year.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies